November 6th, 2013
Why Amarin Has To Finish Its Big Fish Oil Study
CardioExchange Editors, Staff
The following post is by Matt Herper, who covers science and medicine for Forbes magazine. When a panel of experts appointed by the Food and Drug Administration said the agency should deny Amarin Pharmaceuticals a broader marketing approval for its fish oil pill Vascepa, the company’s shares tanked 60%, making it the worst-performing biotechnology stock on […]
NEJM Journal Watch — Recent Cardiology Articles- A Novel Agent Fails to Improve Outcomes in Diabetic Cardiomyopathy
- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus